An observational study in Uveitis, sponsored by Meyer Children's Hospital IRCCS. Recruiting at 19 sites in 5 countries. Open to participants aged 1 Year to 16 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Meyer Children's Hospital IRCCS · Observational
Uveitis is an inflammatory disease of the uvea, one of the highly vascularized fundamental structures of the eye. It is a rare condition in children, with an incidence in the pediatric population ranging from 2% to 14% of all uveitis cases. The diagnosis and management of patients with uveitis rely on a multidisciplinary approach involving an ophthalmologist, a rheumatologist, and an infectious disease specialist to establish the correct diagnosis and assess the involvement of other organs. In Italy, there is no national or regional registry for non-infectious chronic uveitis as per the Prime Ministerial Decree (DPCM) of March 3, 2017 (Identification of surveillance systems and registries for mortality, tumors, and other diseases). However, many clinical centers adopt data recording systems to evaluate the quality of care and to study diseases and outcomes. The Universitary Hospital Meyer Institute Research Hospital (IRCCS) is a national referral center for managing these pediatric cases of non-infectious chronic uveitis, estimated to constitute 95% of all pediatric uveitis cases
299 studies on the registry are indexed under Uveitis; 32 are open to participants now.
This study's planned enrollment of 290 is above the median of 107 across 104 observational studies indexed under Uveitis.
Browse Uveitis studies →Meyer Children's Hospital IRCCS is the lead sponsor of 78 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The data of patients who have been under the care of the hospital since 2010 will be included, and new patients diagnosed from the date of Ethical Committee approval onwards for the next 10 years will also be included
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Describe a population of paediatric patients with chronic non-infectious uveitis
* Frequency of each aetiology of uveitis * Frequency of signs and symptoms at onset of uveitis * Frequency of laboratory findings * Frequency of each anatomical subtype of uveitis
Time frame: thorugh the study and after 1 year
Describe a population of paediatric patients with chronic non-infectious uveitis
* Frequency of complications at onset, 6 months, 12 months, 2 years, then every year * Frequency of impaired visual acuity (LogMAR0.4-1) and blindness (LogMAR\>=1) at onset and at different time points (6 months, 12 months, 18 months, 2 years, then every year)
Time frame: 6 months, 12 months, 2 years and then every year
Identify any differences between the different forms of uveitis in terms of characteristics and outcomes
* Frequency of complications and impaired visual acuity * Description of laboratory characteristics
Time frame: thorugh the study and after 1 year
Identify risk factors for a more severe course
Percentages of children with impaired visual acuity * Percentages of children with ocular complications
Time frame: thorugh the study and after 1 year
Frequency achievement of response for each drug according to the definition of response
Frequency achievement of response for each drug according to the definition of response of the MIWGUC group
Time frame: thorugh the study and after 1 year
Time to archieve the response after drug initiation
Time to archieve the response after drug initiation
Time frame: thorugh the study and after 1 year
Achievement of inactive disease on therapy according to the definition of MIWGUC
Achievement of inactive disease on therapy according to the definition of MIWGUC
Time frame: thorugh the study and after 1 year
Time to achieve inactive disease on therapy according to the definition of MIWGUC
Time to achieve inactive disease on therapy according to the definition of MIWGUC
Time frame: thorugh the study and after 1 year
Presence and percentages of flares on therapy after achievement of remission on therapy
Presence and percentages of flares on therapy after achievement of remission on therapy
Time frame: thorugh the study and after 1 year
Time to the first flare on therapy
Time to the first flare on therapy
Time frame: thorugh the study and after 1 year
Time to flare after drug withdrawal
Time to flare after drug withdrawal * Proportion of Flare after drug withdrawal in general at the last available follow-up * Proportion of children who flared after drug withdrawal at 6, 12 and 18 months, 2 years then every year
Time frame: 6, 12 and 18 months, 2 years then every year
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Meyer Children's Hospital IRCCS